New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer - Scorecard - MDSpire

New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer

A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).

  • By

  • June 3, 2026

  • 4 min

Share

Clinical Scorecard: New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer

At a Glance

CategoryDetail
ConditionLung Cancer
Key MechanismsAggressive neuroendocrine-like biology identified through advanced transcriptomic profiling.
Target PopulationPatients with non-small cell lung cancer (NSCLC) exhibiting aggressive neuroendocrine-like features.
Care SettingOncology research and clinical practice.

Key Highlights

  • Identified a subset of NSCLC tumors with aggressive neuroendocrine-like biology.
  • These tumors are associated with shorter survival and increased metastasis.
  • Advanced molecular testing may help personalize treatment approaches.
  • Tumors often lack PD-L1 expression and express high levels of neuroendocrine markers.
  • Potentially targetable markers include DLL3, SEZ6, and SSTR2.

Guideline-Based Recommendations

Diagnosis

  • Utilize advanced molecular profiling to identify high-risk tumors.

Management

  • Consider neuroendocrine-directed therapies for patients with identified markers.

Monitoring & Follow-up

  • Monitor for aggressive behavior and metastasis in identified tumors.

Risks

  • Patients may receive inadequate treatment if tumors are misclassified.

Patient & Prescribing Data

Patients diagnosed with NSCLC that may exhibit neuroendocrine-like features.

Personalized treatment strategies based on molecular characteristics rather than histological appearance.

Clinical Best Practices

  • Implement advanced transcriptomic profiling in lung cancer diagnostics.
  • Adopt a biology-driven approach to lung cancer classification and treatment.

Related Resources & Content

Original Source(s)

New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer

  • by

  • June 3, 2026

Related Content

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min
2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
New AI-Enabled Technology Supports Radiology Follow-Up Throughout Baptist Health

Baptist Health Herbert Wertheim Cancer Institute has launched Eon, an AI-enabled software platform that analyzes radiology reports and helps identify and prioritize incidental findings for clinical review, in an effort to support timely, coordinated patient care.

  • by

  • July 1, 2026

  • 2 min